ZIOPHARM Oncology CEO Kevin Boyle's 2023 pay slips 4% to $1.7M
ZIOPHARM Oncology reports 2023 executive compensation
By ExecPay News
Published: April 26, 2024
ZIOPHARM Oncology reported fiscal year 2023 executive compensation information on April 26, 2024.
In 2023, three executives at ZIOPHARM Oncology received on average a compensation package of $1M, a 13% decrease compared to previous year.
Average pay of disclosed executives at ZIOPHARM Oncology
Kevin S. Boyle, Sr, Chief Executive Officer, received $1.7M in total, which decreased by 4% compared to 2022. 40% of Boyle's compensation, or $690K, was in option awards. Boyle also received $618K in salary and $410K in other compensation.
Melinda Lackey, SVP, Legal & Administration, received a compensation package of $702K, which decreased by 8% compared to previous year. 45% of the compensation package, or $313K, was in other compensation.
Drew Deniger, VP, Research and Development, earned $630K in 2023, a 34% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 26, 2024.